Table. 3—

Comparison of the use of alteplase infusions with bolus-dose alteplase in the treatment of massive pulmonary embolism (PE)

Study or subcategoryAlteplase infusion n/NAlteplase bolus n/NWeight %Fixed RR (95% CI)
All-cause mortality#
 Goldhaber et al. 201/275/601000.44 (0.05–3.62)
 Sors et al. 190/170/36NE
 Subtotal##44961000.44 (0.05–3.62)
Deaths due to bleeding
 Goldhaber et al. 200/272/601000.44 (0.02–8.78)
 Sors et al. 190/170/36NE
 Subtotal##44961000.44 (0.02–8.78)
Deaths due to recurrent PE+
 Goldhaber et al. 201/273/601000.74 (0.08–6.80)
 Sors et al. 190/170/36NE
 Subtotal##44961000.74 (0.08–6.80)
Major bleeding episodes§
 Goldhaber et al. 206/278/6033.211.67 (0.64–4.34)
 Sors et al. 191/173/3612.870.71 (0.08–6.30)
 Meyer et al. 235/1928/11353.911.06 (0.47–2.41)
 Subtotal##632091001.22 (0.67–2.21)
Recurrent PEƒ
 Goldhaber et al. 202/274/6065.931.11 (0.22–5.70)
 Sors et al. 191/172/3634.071.06 (0.10–10.88)
 Subtotal##44961001.09 (0.29–4.17)
  • RR: relative risk; CI: confidence interval; NE: not estimable. #: total events, 1 (alteplase infusion), 5 (alteplase bolus); test for heterogeneity, not applicable; test for overall effect, z = 0.76, p = 0.45. : total events, 0 (alteplase infusion), 2 (alteplase bolus); test for heterogeneity, not applicable; test for overall effect, z = 0.54, p = 0.59. +: total events, 1 (alteplase infusion), 3 (alteplase bolus); test for heterogeneity, not applicable; test for overall effect, z = 0.27, p = 0.79. §: total events, 12 (alteplase infusion), 39 (alteplase bolus); test for heterogeneity, Chi-squared = 0.76, df = 2 (p = 0.68), l2 = 0%; test for overall effect, z = 0.65, p = 0.52. ƒ: total events, 3 (alteplase infusion), 6 (alteplase bolus); test for heterogeneity, Chi-squared = 0.00, df = 1 (p = 0.97), l2 = 0%; test for overall effect, z = 0.13, p = 0.90. ##: 95% CI.